Attention Turns to Specialty Pharmacy

Area of Science:

• Health Economics
• Pharmaceutical Policy
• Biotechnology

Background:

• Specialty biotech drugs constitute a small percentage of prescriptions but disproportionately high pharmacy costs.
• Projected to increase to 50% of pharmacy costs within three years, these drugs pose significant financial challenges.
• US costs for specialty drugs are considerably higher than in other nations, raising global competitiveness concerns.

Purpose of the Study:

• To examine current specialty drug trends and their financial implications.
• To discuss strategies for balancing patient access to specialty drugs with their economic impact.
• To review existing specialty drug management practices and provide future considerations for plan sponsors.

Main Methods:

• Analysis of prescription data and pharmacy cost trends.
• Review of international drug pricing comparisons.
• Examination of current specialty drug management programs and policies.

Main Results:

• Specialty biotech drugs represent a substantial and escalating component of overall healthcare expenditure.
• Significant price disparities exist for these drugs between the US and other countries.
• Current management approaches are evolving to address the rising costs and access issues.

Conclusions:

• Specialty drug cost management is an ongoing challenge for benefits budgets.
• Strategic management options can help mitigate the financial impact of specialty biotech drugs.
• Balancing access to innovative therapies with cost containment remains a key objective for plan sponsors.